(AGEN) Agenus - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00847G8042
AGEN: Cancer, Vaccines, Antibodies, Adjuvants
Agenus Inc. (NASDAQ: AGEN) is a clinical-stage biotechnology company dedicated to advancing immuno-oncology treatments. Their approach leverages innovative technologies to develop targeted therapies, focusing on monoclonal antibodies and cancer treatments. The company utilizes Retrocyte Display, a platform for identifying antibodies, crucial for developing targeted therapies, and QS-21 Stimulon, a saponin-based adjuvant enhancing vaccine efficacy.
Their pipeline includes Balstilimab, an anti-PD-1 inhibitor in Phase II for cervical cancer, highlighting its role in a well-established area of oncology. AGEN1181, a CTLA-4 inhibitor in Phase II, targets challenging cancers like pancreatic and melanoma, showcasing its potential in immunotherapy. AGEN2373, targeting CD137, aims to enhance anti-tumor responses, while AGEN1423 addresses CD73 and TGF-β, modulating the tumor microenvironment. AGEN1571, an ILT2 antibody, and BMS-986442, a TIGIT bispecific, represent novel approaches in immune modulation and bispecific therapy.
Additional candidates include INCAGN1876 (GITR agonist), INCAGN2390 (TIM-3), and INCAGN2385 (LAG-3), each targeting specific immune checkpoints. MK-4830 targets ILT4 in Phase II, and UGN-301 addresses urinary tract cancers. AGEN1884, a first-gen anti-CTLA-4, demonstrates their range in therapeutic development.
Collaborations with pharmaceutical leaders like BMS, Incyte, Merck, and Gilead underscore their strategic partnerships, enhancing resource access and expertise. Founded in 1994, Agenus rebranded in 2011, reflecting a shift towards immunotherapy focus.
3-Month Forecast:
Technically, AGENs stock is currently at $2.41, below its 20 and 50-day SMAs, indicating bearish momentum. With a moderate ATR of 0.29, volatility is expected. The stock may face continued pressure unless it surpasses key resistance levels.
Fundamentally, Agenus market cap is $72.96M with a high P/B of 218.61 and P/S of 0.45. The RoE of 260.68 suggests significant growth potential, though the company may not yet be profitable. Investors may remain cautious, awaiting pipeline catalysts for positive movement.
Additional Sources for AGEN Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AGEN Stock Overview
| Market Cap in USD | 44m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2000-02-04 |
AGEN Stock Ratings
| Growth 5y | -94.0% |
| Fundamental | -1.22% |
| Dividend | 0.0% |
| Rel. Strength Industry | -83.2 |
| Analysts | 3.4/5 |
| Fair Price Momentum | 1.09 USD |
| Fair Price DCF | - |
AGEN Dividends
No Dividends PaidAGEN Growth Ratios
| Growth Correlation 3m | -13% |
| Growth Correlation 12m | -88% |
| Growth Correlation 5y | -88.3% |
| CAGR 5y | -46.78% |
| CAGR/Max DD 5y | -0.47 |
| Sharpe Ratio 12m | -1.28 |
| Alpha | -124.11 |
| Beta | 5.45 |
| Volatility | 99.82% |
| Current Volume | 940.4k |
| Average Volume 20d | 388.5k |
As of March 15, 2025, the stock is trading at USD 1.86 with a total of 940,421 shares traded.
Over the past week, the price has changed by -20.85%, over one month by -47.01%, over three months by -34.28% and over the past year by -84.49%.
Neither. Based on ValueRay Fundamental Analyses, Agenus is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -1.22 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AGEN as of March 2025 is 1.09. This means that AGEN is currently overvalued and has a potential downside of -41.4%.
Agenus has received a consensus analysts rating of 3.40. Therefor, it is recommend to hold AGEN.
- Strong Buy: 1
- Buy: 0
- Hold: 4
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AGEN Agenus will be worth about 1.3 in March 2026. The stock is currently trading at 1.86. This means that the stock has a potential downside of -29.57%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 7 | 276.3% |
| Analysts Target Price | 8 | 330.1% |
| ValueRay Target Price | 1.3 | -29.6% |